TNYA Tenaya Therapeutics, Inc.
$0.40▼ -1.41%
Healthcare
Other
Volume 188.2K
Avg Volume (10D) 4.78M
Key Metrics & Fundamentals
Market Cap
$91.81M
P/E Ratio
–
Div Yield
0.00%
52W Range
0.36 - 1.65
% vs 50 MA
-31.80%
% vs 200 MA
-43.07%
RSI-14
32.3
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.62
Free Cash Flow
-$3.71M
Gross Rev
$1.11M
Gross Profit
$1.11M
EBITDA
$3.99M
COGS
–
Operating Exp
$22.01M
Operating Income
-$20.90M
EBIT
-$20.90M
Pretax Income
-$43.39M
Net Income
-$43.39M
EPS (Diluted)
-0.20
Price & Volume History
Loading chart…
Recent News
Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
GlobeNewswire · Sep 14, 2026 8:30 AM ET
Treasury yields rise as investors raise bets on Fed rate hike: AlphaCheck
Yahoo Finance · Sep 10, 2026 9:56 AM ET
Tenaya Therapeutics to Participate in Upcoming September Investor Conferences
GlobeNewswire · Sep 3, 2026 4:30 PM ET
Tenaya Therapeutics Eyes Q4 Updates for Cardiac Gene Therapies, TN-301
MarketBeat · Aug 18, 2026 4:01 AM ET
Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 5, 2026 4:05 PM ET
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
GlobeNewswire · Aug 4, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See TNYA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.